A woman presented with a BIRADS-5 breast lesion. Which of the following is a good prognostic factor for this lesion?

Explanation

## Correct Answer: A. ER positive ER (estrogen receptor) positivity is a well-established **good prognostic factor** in breast cancer, particularly in BIRADS-5 lesions (highly suspicious for malignancy). ER-positive tumors are typically **hormone-responsive**, allowing treatment with endocrine therapy (tamoxifen, aromatase inhibitors) which significantly improves disease-free and overall survival. These tumors tend to be **lower grade, slower-growing**, and have better response to targeted therapy. In the Indian context, ER-positive breast cancers represent approximately 60–70% of all breast malignancies and are associated with longer median survival compared to ER-negative subtypes. The presence of ER positivity allows oncologists to employ hormonal manipulation strategies, which are cost-effective and widely available in Indian cancer centers. ER-positive tumors also correlate with **luminal A and luminal B subtypes** (by PAM50 classification), which carry better prognosis than triple-negative or HER2-enriched subtypes. This makes ER positivity a critical predictive and prognostic marker that guides both treatment selection and patient counseling regarding long-term outcomes. ## Why the other options are wrong **B. p53 positive** — p53 positivity (detected by immunohistochemistry) indicates **p53 gene mutation or overexpression**, which is a **poor prognostic marker**. p53 mutations are associated with aggressive, high-grade tumors, increased genomic instability, and resistance to chemotherapy and radiation. This is the opposite of a good prognostic factor. NBE may trap students who confuse 'positive' immunostaining with 'positive outcome'—p53 positivity predicts worse prognosis, not better. **C. High Ki-67** — **High Ki-67 index** (>20–30%) is a **poor prognostic marker** indicating high cellular proliferation and aggressive tumor behavior. Ki-67 is a proliferation marker; elevated levels correlate with shorter disease-free survival, higher grade, and increased likelihood of recurrence. High Ki-67 tumors are typically ER-negative and respond poorly to hormonal therapy. This is a negative prognostic factor, not a positive one. **D. BRCA-1 positive** — **BRCA-1 mutation positivity** indicates **hereditary breast cancer predisposition**, not a prognostic marker of the current tumor. While BRCA-1 mutations increase lifetime breast cancer risk and are associated with earlier onset and higher-grade tumors, BRCA-1 positivity itself is a **risk factor, not a prognostic factor** for the existing lesion. Patients with BRCA-1 mutations often have triple-negative cancers with worse prognosis. This confuses genetic predisposition with tumor biology. ## High-Yield Facts - **ER positivity** is the single most important good prognostic factor in breast cancer, enabling endocrine therapy and predicting longer survival. - **p53 mutations** (detected as p53 positivity on IHC) are poor prognostic markers associated with aggressive, high-grade, chemotherapy-resistant tumors. - **High Ki-67 index** (>20–30%) indicates rapid proliferation and poor prognosis; low Ki-67 (<10%) suggests indolent behavior. - **BRCA-1 mutations** are germline predisposition factors, not tumor prognostic markers; they increase risk of triple-negative, aggressive cancers. - **Luminal A (ER+, PR+, HER2−, low Ki-67)** has the best prognosis; **triple-negative (ER−, PR−, HER2−)** has the worst prognosis among breast cancer subtypes. - In India, ER-positive breast cancers comprise ~60–70% of cases and respond well to tamoxifen and aromatase inhibitors, making ER status critical for treatment planning. ## Mnemonics **GOOD Prognostic Factors in Breast Cancer** **G**rade I–II, **O**utcome (ER+/PR+), **O**lder age, **D**iploid DNA. ER/PR positivity = hormone-responsive = better prognosis. **BAD Prognostic Factors (Remember as OPPOSITES)** **B**RCA mutations, **A**naplastic (Grade III), **D**iploid (aneuploid DNA). Also: p53+, HER2+, high Ki-67, triple-negative. ## NBE Trap NBE may trap students by presenting "positive" immunostaining (p53+, BRCA+) as if positivity = good outcome. In reality, p53 positivity = poor prognosis, and BRCA positivity = genetic risk, not tumor prognosis. Only ER positivity truly means "positive for good outcome." ## Clinical Pearl In Indian breast cancer practice, ER status is the first immunohistochemical marker ordered on all BIRADS-5 lesions. An ER-positive, HER2-negative, low-grade tumor in a 50-year-old woman can be managed with tamoxifen monotherapy or aromatase inhibitors, avoiding chemotherapy toxicity—a significant advantage in resource-limited settings. _Reference: Bailey & Love Ch. 52 (Breast); Robbins Ch. 24 (Breast Pathology); Harrison Ch. 375 (Breast Cancer)_